TY - JOUR
T1 - Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC)
AU - Blumenschein, George R.
N1 - Funding Information:
Acknowledgments This work was supported by Boehringer Ingelheim Pharmaceuticals, Inc (BIPI). Writing and editorial assistance was provided by Staci Heise, PhD, of MedErgy, which was contracted by BIPI for these services. The author meets criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE), was fully responsible for all content and editorial decisions, and was involved at all stages of manuscript development. The author received no compensation related to the development of the manuscript.
PY - 2012/8
Y1 - 2012/8
N2 - Standard therapy for advanced or metastatic non-small cell lung cancer (NSCLC) has primarily consisted of traditional cytotoxic chemotherapy, although use of targeted therapies has been approved in specific settings. Antiangiogenic agents represent a promising therapeutic strategy for treatment of advanced NSCLC. Bevacizumab is currently approved when given in combination with firstline platinum-based therapy in selected patients with nonsquamous NSCLC. Bevacizumab may also provide benefit in other clinical settings, as a part of a combination or maintenance strategy. Other antiangiogenic agents under development, including multi-targeted kinase inhibitors (MTKIs) and antibody-based agents, have exhibited mixed results in the NSCLC population. Published efficacy and safety data from clinical trials for antiangiogenic agents are reviewed, with an emphasis on novel agents and novel settings for established agents. Identification of biomarkers associated with improved efficacy may help select patients likely to receive the most benefit from these agents and may improve outcomes through development of personalized therapeutic strategies.
AB - Standard therapy for advanced or metastatic non-small cell lung cancer (NSCLC) has primarily consisted of traditional cytotoxic chemotherapy, although use of targeted therapies has been approved in specific settings. Antiangiogenic agents represent a promising therapeutic strategy for treatment of advanced NSCLC. Bevacizumab is currently approved when given in combination with firstline platinum-based therapy in selected patients with nonsquamous NSCLC. Bevacizumab may also provide benefit in other clinical settings, as a part of a combination or maintenance strategy. Other antiangiogenic agents under development, including multi-targeted kinase inhibitors (MTKIs) and antibody-based agents, have exhibited mixed results in the NSCLC population. Published efficacy and safety data from clinical trials for antiangiogenic agents are reviewed, with an emphasis on novel agents and novel settings for established agents. Identification of biomarkers associated with improved efficacy may help select patients likely to receive the most benefit from these agents and may improve outcomes through development of personalized therapeutic strategies.
KW - Angiogenesis inhibitor
KW - Biological marker
KW - Carcinoma
KW - Non-small cell lung
KW - Protein-tyrosine kinase
KW - Receptor
KW - Vascular endothelial growth factor
UR - http://www.scopus.com/inward/record.url?scp=84866734165&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866734165&partnerID=8YFLogxK
U2 - 10.1007/s10637-011-9750-1
DO - 10.1007/s10637-011-9750-1
M3 - Review article
C2 - 21987350
AN - SCOPUS:84866734165
SN - 0167-6997
VL - 30
SP - 1802
EP - 1811
JO - Investigational New Drugs
JF - Investigational New Drugs
IS - 4
ER -